---
title: "FOXO TECHNOLOGIES INC | 10-Q: FY2025 Q2 Revenue: USD 5.218 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253690375.md"
datetime: "2025-08-19T20:04:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253690375.md)
  - [en](https://longbridge.com/en/news/253690375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253690375.md)
---

# FOXO TECHNOLOGIES INC | 10-Q: FY2025 Q2 Revenue: USD 5.218 M

Revenue: As of FY2025 Q2, the actual value is USD 5.218 M.

EPS: As of FY2025 Q2, the actual value is USD -0.21.

### Healthcare Segment

-   **Net Revenues**: $5.2 million for the three months ended June 30, 2025, compared to $20,187 for the same period in 2024. For the six months ended June 30, 2025, net revenues were $8.4 million compared to $20,187 in 2024. The increase is primarily due to the acquisition of Myrtle and RCHI, with RCHI contributing $7.4 million in the six months ended June 30, 2025.
-   **Operating Expenses**: $3.9 million for the three months ended June 30, 2025, compared to $88,244 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $7.9 million compared to $88,244 in 2024.
-   **Segment Earnings (Loss)**: $1.3 million for the three months ended June 30, 2025, compared to a loss of $66,723 for the same period in 2024. For the six months ended June 30, 2025, segment earnings were $0.4 million compared to a loss of $66,723 in 2024.

### Labs Segment

-   **Net Revenues**: $7,816 for the three months ended June 30, 2025, compared to $7,287 for the same period in 2024. For the six months ended June 30, 2025, net revenues were $16,305 compared to $14,467 in 2024.
-   **Operating Expenses**: $41,259 for the three months ended June 30, 2025, compared to $718,078 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $72,753 compared to $884,708 in 2024.
-   **Segment Loss**: $33,443 for the three months ended June 30, 2025, compared to $710,791 for the same period in 2024. For the six months ended June 30, 2025, segment loss was $56,448 compared to $870,241 in 2024.

### Future Outlook and Strategy

-   **Healthcare Segment**: The company plans to grow this division by acquisition and investment in new operations in targeted areas.
-   **Myrtle Recovery Centers, Inc.**: Plans to expand the business model by acquiring additional operating facilities and replicating the model in other rural hospital properties or suitable premises.
-   **FOXO Labs**: Focus on commercializing epigenetic biomarker technology and pursuing the spin-off of its FOXO Labs, Inc. subsidiary.

### Related Stocks

- [FOXOW.US](https://longbridge.com/en/quote/FOXOW.US.md)

## Related News & Research

- [FACTBOX-IPO-bound SpaceX's board is stacked with Musk empire loyalists](https://longbridge.com/en/news/287206089.md)
- [INSTANT VIEW-SpaceX files long awaited IPO, creating a fresh AI play](https://longbridge.com/en/news/287124128.md)
- [ANALYSIS-Why SpaceX's mega IPO may not signal a broader rebound in listings](https://longbridge.com/en/news/287215490.md)
- [GRAPHIC-Major takeaways from Magnificent Seven's AI-fueled earnings](https://longbridge.com/en/news/287224928.md)
- [SanDisk (SNDK) Has Surprised Me. I'm Still Not Buying the Stock Yet](https://longbridge.com/en/news/287177163.md)